渲染靶标:SSR
Render Timestamp: 2025-03-17T06:26:34.513Z
Commit: a619ae74f66dae0f27639e88da12bcf600e46428
XML generation date: 2025-03-07 13:06:15.763
Product last modified at: 2024-05-30T07:13:50.505Z
1% for the Planet 标识
PDP - Template Name: Polyclonal Antibody
PDP - Template ID: *******59c6464

CYR61 Antibody #11952

We recommend the following alternatives

Filter:
  • WB
Western Blotting Image 1: CYR61 Antibody
Western blot analysis of extracts from various cell lines using CYR61 Antibody.
This product is discontinued

Inquiry Info. # 11952

Please see our recommended alternatives.

Supporting Data

REACTIVITY H
SENSITIVITY Endogenous
MW (kDa) 41
SOURCE Rabbit
Application Key:
  • WB-Western Blotting 
Species Cross-Reactivity Key:
  • H-Human 

Product Information

Product Usage Information

Application Dilution
Western Blotting 1:1000

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at –20°C. Do not aliquot the antibody.

Protocol

Specificity / Sensitivity

CYR61 Antibody recognizes endogenous levels of total CYR61 protein.

Species Reactivity:

Human

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Pro171 of human CYR61 protein. Antibodies are purified by protein A and peptide affinity chromatography.

Background

Cysteine-rich protein 61 (CYR61, CCN1) is a secreted, matrix-associated protein belonging to the CCN family, a protein group characterized primarily by its high cysteine content (1). CYR61 regulates diverse cellular events including cell proliferation, differentiation, angiogenesis, and extracellular matrix formation. Research studies have implicated CYR61 in the development or progression of various cancers, including breast, prostate, lung, and hepatocellular carcinoma (1-4). Notably, its role in promoting cancer progression appears to be context-dependent. For example, investigators have shown that overexpression of CYR61 was positively associated with invasiveness of breast cancer cell lines (2), whereas in primary prostate tumors, expression levels were inversely correlated with tumor aggressiveness (3). In additional research studies of hepatocellular carcinoma, where CYR61 expression was positively associated with cancer progression, CYR61 was shown to be transcriptionally regulated by the Wnt/β-catenin signaling pathway (1).
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
All other trademarks are the property of their respective owners. Visit our Trademark Information page.